Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus
AssigneesInstitut National De La Sante Et De La Recherche Medicale (Inserm), Universite Paris Diderot—Paris 7
InventorsNicolas CHARLES, Christophe PELLEFIGUES
Life of this patent
Estimating the term…
Abstract
A PTGDR-1 antagonist, a PTGDR-2 antagonist, a dual PTGDR-1/PTGDR-1 antagonist, or a combination of PTGDR-1 antagonist and PTGDR-2 antagonist, and pharmaceutical compositions containing them, are provided to patients in need thereof to prevent or treat disease including systemic lupus erythematosus (SLE).
Claims15
A method for preventing and/or treating SLE in a patient in need thereof, wherein said method comprises administering said patient with a PTGDR-1 antagonist.
A method for preventing and/or treating SLE in a patient in need thereof, wherein said method comprises administering said patient with a pharmaceutical composition comprising a PTGDR-1 antagonist and a PTGDR-2 antagonist, or a dual PTGDR-1/PTGDR-2 antagonist.
Dependencies are inferred from the claim text.